 Immunic Inc NASDAQ: IMUX has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis PSC, a rare liver disease characterized by inflamed and narrow bile ducts, thus preventing bile from flowing correctly. 27.3 of the patients in the per-protocol population had a clinically relevant reduction of serum alkaline phosphatase higher than 25 at week 24, without an increase in liver biochemistry of more than 33, as compared to baseline. 